In this article, we will list the 5 Best European Growth Stocks to Buy. Please visit 10 Best European Growth Stocks to Buy if you would like to see the extended list and the methodology behind it.
5. On Holding AG (NYSE:ONON)
On May 15, 2026, On Holding AG (NYSE:ONON) disclosed insider purchases by several company executives and founders. Co-CEO Caspar Coppetti purchased 60,000 shares at an average price of $36.64 per share for a total investment of about $2.2M. Following the transaction, Coppetti owned approximately 2.38 million shares of the company. Co-CEO David Allemann also purchased 60,000 shares at an average price of $36.64 per share for roughly $2.2M, increasing the holding to approximately 2.84 million shares. Meanwhile, co-founder and director Olivier Bernhard acquired 60,000 shares at the same average purchase price for a total value of about $2.2M. Bernhard now owns roughly 5.16 million shares of On Holding.
On May 13, 2026, Telsey Advisory lowered the firm’s price target on On Holding AG (NYSE:ONON) to $51 from $60 while maintaining an Outperform rating on the shares. Telsey said the company’s constant-currency Q1 sales growth of 26.5% continues to stand out within the sporting goods sector and reflects ongoing market share gains across both performance and lifestyle categories. The firm added that the reduced price target mainly reflects lower broader market valuation multiples.
Truist analyst Joseph Civello also lowered the firm’s price target on On Holding AG (NYSE:ONON) to $48 from $55 while maintaining a Buy rating on the shares. Truist said investor debate around the stock remains active, with stronger-than-expected profitability highlighting the advantages of the brand’s premium positioning, while softer U.S. direct-to-consumer trends continue to raise questions around the company’s long-term growth trajectory. The firm added that it still sees meaningful momentum behind the brand, supported by an affluent customer base and relatively low market penetration.
On Holding AG (NYSE:ONON) develops and markets athletic footwear, apparel, and performance sports products globally under the On brand.
4. Transocean Ltd. (NYSE:RIG)
On May 7, 2026, Barclays upgraded Transocean Ltd. (NYSE:RIG) to Overweight from Equal Weight and raised the firm’s price target to $8 from $6. The firm also upgraded its broader view on the energy services sector to Positive from Neutral, arguing that the group is facing its strongest setup in roughly two decades. Barclays said that once the current supply shock subsides, oil prices are likely to remain structurally higher, which could drive increased upstream spending activity in 2027 and 2028. The firm added that geopolitical developments in the Middle East could further support a multi-year increase in upstream investment, potentially leading to a new earnings revision cycle and valuation re-rating across energy services names.
On May 4, 2026, Transocean Ltd. (NYSE:RIG) reported Q1 revenue totaled $1.08B, ahead of the consensus estimate of $1.03B. As of May 4, 2026, the company’s total backlog stood at approximately $7.1B. President and CEO Keelan Adamson said the company delivered a strong start to the year, highlighted by new or extended contracts across five rigs during the quarter. Adamson noted that the backlog reflects continued demand for Transocean’s differentiated offshore assets and carries an implied average day rate above $450,000. Management also pointed to better-than-expected quarterly revenue and adjusted EBITDA margin above 40%. The company added that it continued to improve financial flexibility during the quarter through accelerated debt reduction, lower interest expense, and ongoing balance sheet simplification efforts.
For full-year 2026, Transocean expects revenue between $3.8B and $3.9B, compared to the consensus estimate of $3.88B. The company also expects capital expenditures of approximately $150M.
Transocean Ltd. (NYSE:RIG) provides offshore contract drilling services for oil and gas wells globally.
3. CRISPR Therapeutics AG (NASDAQ:CRSP)
On May 13, 2026, Bernstein raised the firm’s price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $56 from $50 while maintaining a Market Perform rating on the shares. Bernstein said the biotech sector has started 2026 strongly, with the group up 11% year-to-date and outperforming both large-cap pharma and the broader S&P 500. The firm added that smaller biotech companies have led the rally and maintained a constructive view on the sector, citing expectations for continued healthy M&A and IPO activity alongside recent FDA leadership changes that could benefit earlier-stage biotech companies.
Meanwhile, BofA lowered the firm’s price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $83 from $86 while maintaining a Buy rating on the shares. The firm said it came away from the company’s first-quarter updates with “few changes to the core thesis,” describing the overall developments as encouraging.
On May 4, 2026, CRISPR Therapeutics AG (NASDAQ:CRSP) reported that first-quarter revenue totaled $1.4M. Chairman and CEO Samarth Kulkarni said the quarter reflected continued execution across the company’s broader gene-editing platform. Kulkarni highlighted the expansion of zugo-cel into additional autoimmune disease indications and continued progress advancing several in vivo liver-directed programs toward clinical development. The company also pointed to continued momentum for CASGEVY. Management added that with a strengthened balance sheet and multiple upcoming catalysts, 2026 could become a defining year for the company.
CRISPR Therapeutics AG (NASDAQ:CRSP) develops gene-editing therapies for serious diseases using its CRISPR/Cas9 platform technology.
2. Cimpress plc (NASDAQ:CMPR)
On May 11, 2026, Cimpress plc (NASDAQ:CMPR) announced that it signed a definitive agreement with CEWE Stiftung & Co. KGaA to acquire its SAXOPRINT and viaprinto businesses. Through the tuck-in acquisition, Cimpress said it will expand its manufacturing footprint in Germany while adding two customer-focused brands to its PrintBrothers upload-and-print segment. SAXOPRINT, based in Dresden, Germany, specializes in high-quality, low-cost production of flyers, brochures, catalogs, magazines, and related print products for business customers. viaprinto, headquartered in Munster, Germany, operates as a reseller focused on business customers through an intuitive ordering experience and additional value-added services.
Together, the two businesses generated EUR 89.6M in revenue during calendar year 2025 with EBITDA margins of approximately 10%. The transaction remains subject to customary closing conditions, including antitrust approval, and is expected to close during the first half of Cimpress’ fiscal 2027. Cimpress also said leadership team members from its PrintBrothers segment are expected to co-invest alongside the company and acquire minority ownership interests in the acquired operations.
On May 6, 2026, Barrington raised the firm’s price target on Cimpress plc (NASDAQ:CMPR) to $113 from $95 while maintaining an Outperform rating on the shares. Barrington said that despite the stock already gaining roughly 38% year-to-date, it still sees additional upside supported by positive estimate revisions and a modest increase in its valuation assumptions.
Cimpress plc (NASDAQ:CMPR) provides mass customization printing and related products across North America, Europe, and other international markets.
1. STMicroelectronics N.V. (NYSE:STM)
On May 15, 2026, Deutsche Bank analyst Robert Sanders raised the firm’s price target on STMicroelectronics N.V. (NYSE:STM) to EUR 42 from EUR 32 while maintaining a Buy rating on the shares.
Last month, Citi analyst Andrew Gardiner also raised the firm’s price target on STMicroelectronics N.V. (NYSE:STM) to EUR 52 from EUR 31 and maintained a Buy rating on the shares. Citi described the company’s Q1 report as strong, highlighting revenue and gross margins that came in ahead of expectations. The firm also raised its valuation multiple on the stock to reflect improving momentum.
Earlier in April, STMicroelectronics N.V. (NYSE:STM) reported Q1 EPS of 13c, versus the consensus estimate of 22c. Revenue totaled $3.1B, compared to the consensus estimate of $3.19B. President and CEO Jean-Marc Chery said first-quarter revenue came in above the midpoint of the company’s guidance range, excluding contributions from the acquisition of NXP’s MEMS sensor business. The performance was driven primarily by stronger engaged customer programs within personal electronics and CECP, while gross margin also exceeded the midpoint of guidance due to a more favorable product mix. On a year-over-year basis, first-quarter revenue increased 23%, or 21.4% excluding the acquired MEMS sensor business. Gross margin came in at 33.8%, operating margin was 2.3%, and net income totaled $37M. The company also said that despite ongoing macroeconomic uncertainty, it saw improving demand trends during the quarter, supported by strong bookings activity and normalized inventory levels across distribution channels.
STMicroelectronics N.V. (NYSE:STM) designs, manufactures, and sells semiconductor products across automotive, industrial, personal electronics, and AI-related infrastructure markets globally.
While we acknowledge the potential of STM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than STM and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 AI Stocks with Potential to Rise 1000 Percent and 9 Best American Semiconductor Stocks to Buy According to Analysts
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
